中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (8): 593-597.doi: 10.12144/zgmfskin202508593

• 临床研究 • 上一篇    下一篇

阿布昔替尼治疗中重度痒疹型特应性皮炎疗效评价

白帆,于万龙,许雅波,范丽芳,刘于媛,田赞,雷明君   

  1. 河北中医药大学第一附属医院皮肤一科，河北石家庄，050000
  • 出版日期:2025-08-15 发布日期:2025-07-31

Efficacy of abrocitinib in the treatment of moderate-to-severe prurigo phenotype atopic dermatitis

BAI Fan, YU Wanlong, XU Yabo, FAN Lifang, LIU Yuyuan, TIAN Zan, LEI Mingjun   

  1. Department of Dermatology, the First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050000，China
  • Online:2025-08-15 Published:2025-07-31

PDF (PC)

20

摘要： 目的：评价阿布昔替尼治疗以泛发性结节性痒疹为主要表现的中重度特应性皮炎的疗效及安全性。方法：回顾性分析2023年3月至2024年4月就诊于我院的15例中重度特应性皮炎患者的临床资料，患者接受阿布昔替尼100 mg/d治疗16周，并随访6个月。分析治疗第0、4、8、16周患者的湿疹面积及严重程度指数（EASI）、研究者整体评估（IGA）、瘙痒数字评估量表（NRS）、皮肤病生活质量指数量表（DLQI）评分及检测嗜酸性粒细胞计数、血清总免疫球蛋白E（IgE）水平。记录治疗期间所有不良反应。结果：15例患者治疗16周后EASI、IGA、NRS及DLQI评分均显著下降，EASI、IGA、NRS及DLQI评分由基线的25.41±4.54、4.07±0.70、8.13±1.19、23.60±2.69，分别降至6.11±2.07、0.67±0.49、0.67±0.62、2.73±1.03，差异有统计学意义（均P＜0.05）。治疗第16周时患者血清总IgE水平由基线的(675.13±483.94)IU/mL降至(199.20±139.19)IU/mL，差异有统计学意义（P＜0.05）。12例患者规律治疗16周病情好转后停药，停药1~2个月后复发。1例患者出现一过性脱发，3例患者出现胃肠道反应，2例青少年患者出现轻度痤疮，未报告其他不良事件。结论：阿布昔替尼治疗痒疹型中重度特应性皮炎疗效好，起效快，且具有良好的安全性。

关键词: 特应性皮炎, 痒疹, JAK抑制剂, 阿布昔替尼

Abstract: Objective: To evaluate the clinical efficacy and safety of abrocitinib in treating prurigo phenotype moderate-to-severe atopic dermatitis (AD). Methods: A retrospective analysis was conducted on 15 patients diagnosed with prurigo phenotype moderate-to-severe AD who visited our department from March 2023 to April 2024. All patients received abrocitinib 100 mg/d for 16 weeks and were followed up for 6 months. The Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Numerical Rating Scale for Itch (NRS), and Dermatology Life Quality Index (DLQI) were analyzed at weeks 0, 4, 8, and 16 of treatment. Additionally, eosinophil counts and serum total immunoglobulin E (IgE) levels were measured. Adverse reactions during the treatment period were documented. Results: After 16 weeks of treatment, the EASI, IGA, NRS, and DLQI scores of the 15 patients decreased significantly (P<0.05). Baseline scores of 25.41±4.54, 4.07±0.70, 8.13±1.19, and 23.60±2.69 decreased to 6.11±2.07, 0.67±0.49, 0.67±0.62, and 2.73±1.03 (Ps＜0.05). Serum total IgE levels also significantly decreased from 675.13±483.94 IU/mL to 199.20±139.19 IU/mL (P＜0.05). Twelve patients discontinued the medication following 16 weeks of consistent treatment, and recurrence was observed within 1 to 2 months thereafter. Transient alopecia was observed in one patient, gastrointestinal reactions were noted in three patients, and mild acne was reported in two adolescent patients. No other adverse events were observed. Conclusions: Abrocitinib demonstrates significant efficacy in the treatment of prurigo phenotype moderate-to-severe AD is effetive and safe.

Key words: atopic dermatitis, prurigo, JAK inhibitor, abrocitinib